PMC:7195088 / 20196-20379 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"669","span":{"begin":166,"end":174},"obj":"Species"},{"id":"791","span":{"begin":143,"end":162},"obj":"Chemical"},{"id":"933","span":{"begin":46,"end":55},"obj":"Disease"}],"attributes":[{"id":"A669","pred":"tao:has_database_id","subj":"669","obj":"Tax:9606"},{"id":"A791","pred":"tao:has_database_id","subj":"791","obj":"MESH:C558899"},{"id":"A933","pred":"tao:has_database_id","subj":"933","obj":"MESH:D003643"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" yet recruiting). Primary endpoint: all-cause mortality (follow-up 30 days).\n• Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mil"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T208","span":{"begin":93,"end":104},"obj":"Chemical"},{"id":"T209","span":{"begin":110,"end":121},"obj":"Chemical"},{"id":"T210","span":{"begin":126,"end":137},"obj":"Chemical"},{"id":"T211","span":{"begin":143,"end":162},"obj":"Chemical"},{"id":"T212","span":{"begin":143,"end":152},"obj":"Chemical"},{"id":"T213","span":{"begin":153,"end":162},"obj":"Chemical"}],"attributes":[{"id":"A208","pred":"chebi_id","subj":"T208","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A209","pred":"chebi_id","subj":"T209","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A210","pred":"chebi_id","subj":"T210","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A211","pred":"chebi_id","subj":"T211","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A212","pred":"chebi_id","subj":"T212","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A213","pred":"chebi_id","subj":"T213","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"}],"text":" yet recruiting). Primary endpoint: all-cause mortality (follow-up 30 days).\n• Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mil"}

{"project":"LitCovid-sentences","denotations":[{"id":"T140","span":{"begin":18,"end":76},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":" yet recruiting). Primary endpoint: all-cause mortality (follow-up 30 days).\n• Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mil"}